Inteelabs
Improving Lives Through Precision Biologics
Inteelabs is building a new paradigm in biologics innovation — developing affordable, scalable therapies for neglected and high-impact diseases.
By combining recombinant technologies, platform bioprocessing, and strategic partnerships, we enable rapid development and cost optimization of biologics, including IgY immunotherapies, cardiovascular biosimilars, and multi-asset biologics pipelines.
Our mission is to make life-saving biologics accessible to every patient, everywhere.
We Are Visionaries
Accelerating the Next Generation of Biopharmaceuticals!
We combine synthetic biology, molecular engineering, and advanced bioprocessing to empower biotech innovators worldwide. Our vision is to reshape global healthcare through accessible, effective biologics.
Our mission is to inspire hope and improve patient outcomes by translating bench-scale discoveries into life-changing therapies — shaping a healthier, more inclusive future.
Research & Technology
Platforms That Power Tomorrow’s Biologics
At Inteelabs, we leverage advanced expression platforms across bacterial, yeast, and mammalian systems to develop and manufacture innovative, cost-optimized biologics for therapeutic applications, with a strong focus on neglected and high-burden diseases.
1
Antibody Therapy
3 ONGOING RESEARCH PROJECTS
Inteelabs is developing IgY-based antibody therapies for critical unmet needs in envenomation and zoonotic infections. With ICMR funding, we are advancing recombinant IgY platforms targeting snakebite envenomationand symptomatic rabies, offering safe, scalable, and cost-effective alternatives to conventional antivenoms. These egg-derived antibodies provide high specificity, lower risk of adverse reactions, and sustainable large-scale production, positioning Inteelabs at the forefront of next-generation biologics for neglected public health challenges.
2
Biosimilars Development
6 ONGOING RESEARCH PROJECTS
Inteelabs Reteplase biosimilar, RecPlase™, is currently in preclinical development, targeting advanced thrombolytic therapy.
In addition, we are co-developing five biosimilars in the autoimmune space with a leading pharmaceutical partner, expanding access to high-quality, affordable biologics for critical therapeutic areas.
3
Vaccines
2 ONGOING RESEARCH PROJECTS
Inteelabs COVID-19 vaccine using Virus-Like Particles (VLPs) that mimic the virus structure without containing genetic material. This approach stimulates a strong immune response, ensuring safety, scalability, and broad protection against emerging variants.
4
CRM197
COMMERCIALLY READY
-
100% soluble protein in monomeric state
-
Low HCP, HcDNA, Endotoxins due to secretory expression
-
10 times cost effective as compared to commercially available CRM 197
-
Product and process consistency from shake flask to bioreactor
-
Speed up your conjugate vaccine development programs
-
Avoid hassles of developing it in-house
-
Research grade recombinant CRM197 carrier protein available
-
Cut down hassles of procurement of CRM197 for vaccine development and commercialization
At Inteelabs, we believe that science should serve humanity. Our work stands at the intersection of innovation, health, and purpose — transforming ideas into life-saving biologics. Whether it's developing affordable biosimilars, enabling gene-to-protein solutions, or collaborating on critical vaccine components, we are committed to making cutting-edge biotherapeutics accessible, ethical, and impactful. Because in every protein we build, there's a life we aim to improve.
Team Inteelabs
Join Our Team
We’re looking for highly-motivated and talented people to join our innovative team. Submit your application today to join the Inteelabs journey, share your resume at contact@inteelabs.com!
Scientist: Process Development
Gurugram, Haryana, Delhi NCR
Gurugram, Haryana, Delhi NCR
Gurugram, Haryana, Delhi NCR